Ascorbic Acid News and Research

RSS
Abscorbic acid commonly known as Vitamin C is a water-soluble vitamin, which is necessary in the body to form collagen in bones, cartilage, muscle, and blood vessels and aids in the absorption of iron. Dietary sources of vitamin C include fruits and vegetables, particularly citrus fruits such as oranges.

Severe deficiency of vitamin C causes scurvy. Although rare, scurvy includes potentially severe consequences, and can cause sudden death. Patients with scurvy are treated with vitamin C and should be under medical supervision.

Many uses for vitamin C have been proposed, but few have been found to be beneficial in scientific studies. In particular, research in asthma, cancer, and diabetes remains inconclusive, and no benefits have been found in the prevention of cataracts or heart disease.
Salix first quarter total product revenue increases 62% to $171.1M

Salix first quarter total product revenue increases 62% to $171.1M

Starfruit-shaped nanorods for medical imaging, chemical sensing

Starfruit-shaped nanorods for medical imaging, chemical sensing

Salix third quarter total product revenue increases 81% to $146.2 million

Salix third quarter total product revenue increases 81% to $146.2 million

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Researchers identify three enterotypes in human intestinal bacteria

Researchers identify three enterotypes in human intestinal bacteria

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Lupin grants Salix exclusive worldwide rights to rifaximin

Lupin grants Salix exclusive worldwide rights to rifaximin

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Study: Preterm mothers’ milk contains low concentrations of coenzyme Q10

Study: Preterm mothers’ milk contains low concentrations of coenzyme Q10

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting

Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

Split-dosage method effective for bowel cleansing before colonoscopy: Study

Split-dosage method effective for bowel cleansing before colonoscopy: Study

Bayer receives silver Medical Design Excellence Award for CONTOUR USB blood glucose meter

Bayer receives silver Medical Design Excellence Award for CONTOUR USB blood glucose meter

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals announces novel patient and health care provider support program for HE